Iopromide Injection Obtains Drug Registration Certificate
June 4, 2025
Source: drugdu
86
Starry Pharmaceutical announced on the evening of June 4 that its wholly-owned subsidiary Shanghai Sital recently received the "Drug Registration Certificate" for iopromide injection approved and issued by the National Drug Administration. This drug is indicated for use in diagnostic medication. It is used in blood vessels and body cavities. Computer X-ray tomography (CT) enhancement, arterial angiography and venography, arterial/venous digital subtraction angiography (DSA), especially suitable for cardiovascular angiography, intravenous urography, endoscopic retrograde pancreatocholangiopancreatography (ERCP), arthrography and other body cavity examinations, and cannot be used in the sheath.
https://finance.eastmoney.com/a/202506043421771579.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted July 10, 2025
- Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development July 10, 2025
- Small nucleic acid therapy challenges GLP-1 giants July 10, 2025
- Baili Tianheng BL-B01D1 Update Progress July 10, 2025
- FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema July 10, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
